Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | TYR | P14679 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3681387 | 0.89 | PTGS2 (0.38) | ACHEALDH1A1CA2POLBTYR | |
| SCHEMBL3687571 | 0.88 | ACHE (0.32) | ACHEALDH1A1 | |
| SCHEMBL3681708 | 0.83 | CYP3A4 (0.30) | CYP3A4CYP2D6 | |
| SCHEMBL3681278 | 0.81 | ACHE (0.30) | ACHE | |
| SCHEMBL3679700 | 0.79 | ACHE (0.32) | ACHE | |
| SCHEMBL3681015 | 0.79 | PTGS2 (0.37) | ACHEALDH1A1CA2POLBTYR | |
| SCHEMBL3684349 | 0.77 | CA1 (0.43) | ALDH1A1CA2 | |
| SCHEMBL14594236 | 0.76 | ALDH1A1 (0.46) | ACHEALDH1A1CA2POLBTYR | |
| SCHEMBL31588907 | 0.76 | ALDH1A1 (0.46) | ACHEALDH1A1CA2POLBTYR | |
| SCHEMBL3684407 | 0.76 | PTGS2 (0.37) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2045254-B1 | RARE EARTH METAL COMPLEX, CATALYST FOR POLYMERIZATION AND PROCESS FOR PRODUCING POLYMER | SUMITOMO CHEMICAL CO (JP) | 2013-01-09 | — | — | EP | disclosed |
| US-7851569-B2 | Rare earth metal complex, polymerization catalyst, and process for producing polymer | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2010-12-14 | — | — | US | disclosed |
| US-20090253875-A1 | RARE EARTH METAL COMPLEX, POLYMERIZATION CATALYST AND METHOD FOR PRODUCING POLYMER | SUMITOMO CHEMICAL COMPANY, LIMITED | 2009-10-08 | — | — | US | disclosed |
| EP-2045254-A1 | RARE EARTH METAL COMPLEX, CATALYST FOR POLYMERIZATION AND PROCESS FOR PRODUCING POLYMER | Sumitomo Chemical Company, Limited (JP) | 2009-04-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090253875-A1 | RARE EARTH METAL COMPLEX, POLYMERIZATION CATALYST AND METHOD FOR PRODUCING POLYMER | RPS27L, LAS1L, AGL | ACHE 3462/4885ALDH1A1 4278/4885CA2 992/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.